Whitepaper: High throughput, multi-parametric analysis
This whitepaper overviews how high throughput, multi-parametric analysis accelerates antibody discovery workflows.
List view / Grid view
This whitepaper overviews how high throughput, multi-parametric analysis accelerates antibody discovery workflows.
Researchers from the US have identified several new small molecules that can induce mitophagy in leukaemia cells.
Here Bio-Rad presents the generation of specific anti-CAR T-cell antibodies to show how CAR T-cell analysis benefits from our modular antibody assembly technology using SpyTag-SpyCatcher protein ligation.
9 May 2022 | By PerkinElmer and C4
Looking for a way to address the undruggable proteins in the human body? Watch this free on-demand webinar where industry experts discuss strategies to accelerate TPD drug discovery efforts using high-throughput cell-based assays.
6 May 2022 | By Eurofins Discovery
Watch our free on-demand webinar to learn how to accelerate screening and Structure Activity Relationship (SAR) analysis in the targeted protein degradation (TPD) drug discovery field.
14 April 2022 | By Eurofins Discovery Services
Watch this free on-demand webinar to understand how to rapidly identify selective, specific, potent and tractable hit series with appropriate ADME characteristics to speed up hit-to-lead.
A review of current challenges and goals in cardiac drug discovery and how innovations on human iPSC technology are helping to overcome them.
25 March 2022 | By Bruker Daltonics
Watch our free on-demand webinar to discover how the new timsTOF MPP product solution, with its dedicated MALDI PharmaPulse 2023 HTS software suite, improves data quality and accelerates high-throughput screening in drug discovery.
Novel research has shown that morphological fingerprinting could help identify side effects of new bioactive compounds in drug discovery.
A recent pre-clinical study from Washington University School of Medicine showed that a new class of compounds can potentially improve multiple aspects of metabolic syndrome, including diabetes.
Benefits and key considerations of using human iPSC-derived disease models in drug discovery.
Accelerate your drug discovery workflows efficiently and cost-effectively with lab automation solutions from Beckman Coulter Life Sciences.
In this latest episode, we discuss how small molecule discovery can be automated and how this process saves researchers time and money.
16 December 2021 | By Eurofins DiscoverX and Sanford Burnham Prebys Medical Discovery Institute
Watch this on-demand webinar to learn about orphan GPCRs as drug targets and the challenges related to lead identification.
Researchers have found a quinoxaline-core containing, non-genotoxic lead compound that could treat schistosomiasis following optimisation.